2% human albumin, Hizentra 200 mg/ml solution for subcutaneous injection clinical trials

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 (Subcutaneous Immunoglobulin, Hizentra®) in Adults with Dermatomyositis (DM) – The RECLAIIM Study

This study is testing a new way to treat dermatomyositis, a condition that causes muscle weakness and skin problems. It will see how well a medicine called Hizentra works to improve symptoms and if it's safe, compared to a dummy treatment. We hope to find a better treatment for people with this condition.